Search results for "chino"

showing 10 items of 351 documents

In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

2010

ABSTRACT Anidulafungin, micafungin, and caspofungin in vitro activities against Candida metapsilosis , C. orthopsilosis , and C. parapsilosis were evaluated by MICs and time-kill methods. All echinocandins showed lower MICs (mean MICs, 0.05 to 0.71 mg/liter) and the highest killing rates (−0.06 to −0.05 CFU/ml/h) for C. metapsilosis and C. orthopsilosis rather than for C. parapsilosis (mean MICs, 0.59 to 1.68 mg/liter). Micafungin and anidulafungin killing rates were greater than those determined for caspofungin. None of the echinocandins had fungicidal activity against C. parapsilosis .

Microbiological TechniquesAntifungal AgentsTime FactorsMicrobial Sensitivity TestsIn Vitro TechniquesAnidulafunginMicrobiologychemistry.chemical_compoundEchinocandinsLipopeptidesCandida metapsilosisCaspofunginmedicinepolycyclic compoundsPharmacology (medical)CandidaPharmacologybiologyMicafunginFungi imperfectibiology.organism_classificationbacterial infections and mycosesIn vitroFungicideInfectious DiseaseschemistrySusceptibilityMicafunginAnidulafunginCaspofunginEchinocandinsmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration

2014

Background Anidulafungin is indicated as a first-line treatment for invasive candidiasis in critically ill patients. In the intensive care unit, sepsis is the main cause of acute renal failure, and treatment with continuous renal replacement therapy (CRRT) has increased in recent years. Antimicrobial pharmacokinetics is affected by CRRT, but few studies have addressed the optimal dosage for anidulafungin during CRRT. Patients and methods We included 12 critically ill patients who received continuous venovenous haemodiafiltration to treat acute renal failure. Anidulafungin was infused on 3 consecutive days, starting with a loading dose (200 mg) on Day 1, and doses of 100 mg on Days 2 and 3. …

Microbiology (medical)Antifungal AgentsCritical Illnessmedicine.medical_treatmentHemodiafiltrationAnidulafunginLoading doselaw.inventionSepsisEchinocandinsPharmacokineticslawmedicineHumansCandidiasis InvasivePharmacology (medical)Trough ConcentrationRenal replacement therapyDosingCandidaPharmacologybusiness.industrybacterial infections and mycosesmedicine.diseaseIntensive care unitIntensive Care UnitsInfectious DiseasesAnesthesiaAnidulafunginbusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.

1990

The in vitro activity of cilofungin (LY121019), a new semi-synthetic antifungal agent was evaluated. Potent activity was seen against Candida albicans and Candida tropicalis, with almost identical MIC and MFC results, whereas no activity was seen against any isolates of Candida parapsilosis or three Aspergillus spp. However, MICs were dependent on medium and test conditions chosen. It is concluded that cilofungin has good activity against some medically important yeasts in vitro, and that its in vitro activity depends on the method used.

Microbiology (medical)AntifungalAspergillusbiologymedicine.drug_classAntibioticsCilofunginGeneral Medicinebiology.organism_classificationPeptides CyclicIn vitroCorpus albicansSemi syntheticMicrobiologychemistry.chemical_compoundEchinocandinsInfectious DiseasesAspergilluschemistrymedicinePeptidesCandidaEuropean journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology
researchProduct

Choosing a Study Population for the Evaluation of Antifungal Prophylaxis

2005

Microbiology (medical)Antifungalmedicine.medical_specialtybusiness.industrymedicine.drug_classMEDLINEMicafunginInfectious DiseasesmedicinePopulation studyIntensive care medicinebusinessEchinocandinsmedicine.drugClinical Infectious Diseases
researchProduct

Immunological Diagnosis of Human Cystic Echinococcosis: Utility of Discriminant Analysis Applied to the Enzyme-Linked Immunoelectrotransfer Blot

1999

ABSTRACT An enzyme-linked immunoelectrotransfer blot for the diagnosis of human hydatid disease was performed, and the different antibody responses were analyzed by a discriminant analysis. This multivariate technique gave us, first, a selection of the most important responses against Echinococcus granulosus infection and, second, a procedure for the classification of patients into two groups: patients with hydatid disease and patients without a history of hydatid disease. This method was applied to 67 patients, 25 with active hydatid cysts (24 hepatic and 1 pulmonary) and 42 without a history of hydatid disease and was compared with the results obtained by conventional serology: indirect h…

Microbiology (medical)Echinococcosis HepaticPathologymedicine.medical_specialtyHemagglutinationImmunoblottingClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayBasophil degranulationArticleSerologyImmunological DiagnosisPredictive Value of Testsparasitic diseasesmedicineHumansImmunology and AllergyHyalinebusiness.industryHemagglutinationDiscriminant Analysisdigestive system diseasesBlotAgglutination (biology)Predictive value of testsbusinessClinical Diagnostic Laboratory Immunology
researchProduct

Immunological diagnosis of human hydatid cyst relapse: utility of the enzyme-linked immunoelectrotransfer blot and discriminant analysis.

2000

ABSTRACT A discriminant technique was applied to the different serological patterns obtained by enzyme-linked immunoelectrotransfer blotting (EITB) and by conventional immunological tests, in order to differentiate the residual antibody patterns present in healed hydatidosis from the ones present in patients with active hydatidosis. For this purpose, specific antibodies against Echinococcus granulosus were detected by indirect hemagglutination, agglutination of latex particles, basophil degranulation, and EITB for 23 patients with active hydatidosis and 45 patients with surgically cured hydatidosis. Discriminant analysis of the different serological patterns obtained by EITB and conventiona…

Microbiology (medical)Pathologymedicine.medical_specialtyClinical BiochemistryImmunologyImmunologic TestsBasophil degranulationSerologyImmunoenzyme TechniquesEchinococcosisRecurrenceparasitic diseasesmedicineImmunology and AllergyAnimalsHumansEchinococcus granulosusAntigens Bacterialbiologymedicine.diagnostic_testbiology.organism_classificationmedicine.diseaseEchinococcosisLatex fixation testEchinococcusEchinococcusAbdominal ultrasonographybiology.proteinMicrobial ImmunologyAntibodyClinical and diagnostic laboratory immunology
researchProduct

Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin

2007

ABSTRACT We compared the caspofungin (CAS) susceptibility testing results generated by the disk diffusion (DD) assay with the results of the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BD) reference method for 106 yeast isolates. The isolates represented 11 different fungal species, including Candida albicans ( n = 50), C. parapsilosis ( n = 10), C. glabrata ( n = 10), C. tropicalis ( n = 10), C. guillermondii ( n = 6), C. rugosa ( n = 5), C. krusei ( n = 5), C. kefyr ( n = 2), C. pelliculosa ( n = 2), Saccharomyces cerevisiae ( n = 3), and Geotrichum candidum ( n = 3). The DD assay was performed in supplemented Mueller-Hinton agar with CAS, which was tested at c…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaSusceptibility testingAntifungal AgentsInhibition zonefood.ingredientGeotrichumMicrobial Sensitivity TestsMycologyMicrobiologyDiffusionEchinocandinsLipopeptideschemistry.chemical_compoundfoodCaspofunginCandida albicansAgarCandida albicansCaspofungin Candida Disk diffusion antimicrobial testingbiologyBroth microdilutionFungibiology.organism_classificationYeastchemistryCaspofunginJournal of Clinical Microbiology
researchProduct

International Multicentre Study of Candida auris Infections

2021

Background:Candida auris has emerged globally as a multi-drug resistant yeast and is commonly associated with nosocomial outbreaks in ICUs. Methods: We conducted a retrospective observational multicentre study to determine the epidemiology of C. auris infections, its management strategies, patient outcomes, and infection prevention and control practices across 10 centres from five countries. Results: Significant risk factors for C. auris infection include the age group of 61–70 years (39%), recent history of ICU admission (63%), diabetes (63%), renal failure (52%), presence of CVC (91%) and previous history of antibiotic treatment (96%). C. auris was commonly isolated from blood (76%). Echi…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialtyEchinocandinC. auris Candida Fungi Nosocomial Outbreak ResistanceQH301-705.5Plant ScienceEmergenceresistancechemistry.chemical_compound<i>C. auris</i>Internal medicine<p>C. auris</p>EpidemiologymedicineInfection controlBiology (General)Ecology Evolution Behavior and SystematicsCandidaoutbreakbusiness.industryMortality rateMicafunginnosocomialResistantManagement<i>Candida</i>chemistryCandida aurisAnidulafunginfungiCaspofunginbusinessmedicine.drug
researchProduct

Evaluation of the Disk Diffusion Method Compared to the Microdilution Method in Susceptibility Testing of Anidulafungin against Filamentous Fungi

2008

ABSTRACT Susceptibility testing of anidulafungin (AFG) against 32 mold isolates showed an excellent correlation between disk diffusion (DD) and broth microdilution methods. Based on our data, a 2-μg disk of AFG and a 24-h reading time might represent the best parameters for AFG DD testing against filamentous fungi.

Microbiology (medical)Susceptibility testingAntifungal AgentsDisk Diffusion; Yeasts; CaspofunginDisk diffusion anidulafungin MIC MECMycologyMicrobial Sensitivity TestsBiologyAnidulafunginSettore MED/42 - Igiene Generale E ApplicataDisk DiffusionMicrobiologyEchinocandinsCaspofunginYeastsmedicineHumansAgar diffusion testFood scienceAspergillus Anidulafungin Disk Diffusion1 3 β glucan synthaseAnidulafungineBroth microdilutionFungiAnidulafunginaMycosesAnidulafunginmedicine.drugJournal of Clinical Microbiology
researchProduct